Monitor the special shareholder meeting and regulatory (HSR) clearance timeline for Q3 2026 close. Vertex's large-cap profile and all-cash, non-contingent financing limit downside risk, but integration and pipeline execution risks remain. Watch for any competing bids or regulatory pushback.
Price Chart
Executive Summary
Vertex Pharmaceuticals announced a definitive agreement to acquire Crinetics Pharmaceuticals for $85.00 per share in cash, representing a total equity value of $10.0 billion ($8.8 billion net of cash). The deal adds PALSONIFY (approved, launched oral therapy for acromegaly) and atumelnant (Phase 3 oral ACTH receptor antagonist for congenital adrenal hyperplasia) to Vertex's pipeline, which it expects to generate over $5 billion in combined peak annual revenue. Vertex funded the transaction with cash on hand and a fully committed $4.5 billion bridge financing facility from Bank of America and Morgan Stanley; the deal is expected to close in Q3 2026 and become accretive to non-GAAP operating income in 2029.
Key Financial Metrics
Key Facts
- Vertex acquired Crinetics for $85.00 per share in cash, with a $10.0B equity valuation ($8.8B net of cash).
- The deal adds PALSONIFY, the first and only once-daily oral therapy for acromegaly (launched Oct. 2025, FDA and EMA approved), and atumelnant, a Phase 3 oral ACTH receptor antagonist for congenital adrenal hyperplasia (CAH).
- Vertex expects the combined assets to generate over $5 billion in annual peak revenue and the deal to become accretive to non-GAAP operating income in 2029.
- The merger is expected to close in Q3 2026, subject to Crinetics shareholder approval, HSR clearance, and other customary conditions.
- Vertex secured a $4.5 billion fully committed 364-day bridge loan facility from Bank of America and Morgan Stanley to finance the merger; the deal is not conditioned on financing.
- The termination fee payable by Crinetics to Vertex under specified circumstances is $350,474,425.
Financial Impact
$10.0B equity value ($8.8B net of cash); expects >$5B in combined peak annual revenue from acquired assets
Risk Factors
- Failure to obtain Crinetics shareholder approval or regulatory clearances (HSR, foreign)
- Integration challenges or slower-than-expected commercial uptake of PALSONIFY and atumelnant
- Execution risk in R&D pipeline for atumelnant and other early-stage assets
- Potential termination fee of $350.5M if the deal fails under certain circumstances
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-296710 |
| Document: d113650dex991.htm | 0001193125-26-296710 |
| Document: 0001193125-26-296710-index-headers.html | 0001193125-26-296710 |
| Document: 0001193125-26-296710-index.html | 0001193125-26-296710 |
| Document: 0001193125-26-296710.txt | 0001193125-26-296710 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 7, 2026 12w ago | 8-K | $522.25 $522.81 | ▲ +0.11% | ▼ −1.89% | $506.74 (−2.97%) |
Jul 7, 2026 12w ago | Insider Cluster | $522.25 $522.81 | ▲ +0.11% | ▼ −1.89% | $506.74 (−2.97%) |
Jul 6, 2026 12w ago | Insider Cluster | $529.59 $526.73 | ▼ −0.54% | ▼ −2.26% | $506.74 (−4.31%) |
Jun 3, 2026 17w ago | Insider Cluster | $441.47 $541.69 | ▲ +22.70% | ▲ +21.08% | $506.74 (+14.79%) |
May 19, 2026 19w ago | Insider Cluster | $430.05 $505.75 | ▲ +17.60% | ▲ +12.87% | $506.74 (+17.83%) |
Mar 11, 2026 29w ago | Insider Cluster | $491.96 $428.34 | ▼ −12.93% | ▼ −24.45% | $506.74 (+3.01%) |
Feb 25, 2026 31w ago | Insider Cluster | $482.92 $430.44 | ▼ −10.87% | ▼ −17.82% | $506.74 (+4.93%) |
Feb 25, 2026 31w ago | Insider Cluster | $482.92 $430.44 | ▲ +10.87% | ▲ +17.82% | $506.74 (−4.93%) |
Feb 25, 2026 31w ago | Insider Cluster | $482.92 $430.44 | ▼ −10.87% | ▼ −17.82% | $506.74 (+4.93%) |
Feb 25, 2026 31w ago | Insider Cluster | $482.92 $430.44 | ▼ −10.87% | ▼ −17.82% | $506.74 (+4.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access